{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,17]],"date-time":"2026-03-17T17:41:02Z","timestamp":1773769262862,"version":"3.50.1"},"reference-count":79,"publisher":"Oxford University Press (OUP)","issue":"suppl_8","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2017,11,16]]},"DOI":"10.1093\/infdis\/jix355","type":"journal-article","created":{"date-parts":[[2017,7,24]],"date-time":"2017-07-24T19:11:52Z","timestamp":1500923512000},"page":"S771-S777","source":"Crossref","is-referenced-by-count":34,"title":["Toward a Cure for Hepatitis B Virus Infection: Combination Therapy Involving Viral Suppression and Immune Modulation and Long-term Outcome"],"prefix":"10.1093","volume":"216","author":[{"given":"Di","family":"Wu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qin","family":"Ning","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2017,11,16]]},"reference":[{"key":"key\n\t\t\t\t20171116025732_CIT0001","doi-asserted-by":"crossref","first-page":"2212","DOI":"10.1016\/j.vaccine.2011.12.116","article-title":"Global epidemiology of hepatitis B virus infection: new estimates of age-specific HBsAg seroprevalence and endemicity","volume":"30","year":"2012","journal-title":"Vaccine"},{"key":"key\n\t\t\t\t20171116025732_CIT0002"},{"key":"key\n\t\t\t\t20171116025732_CIT0003","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/j.jhep.2009.05.022","article-title":"Control of cccDNA function in hepatitis B virus infection","volume":"51","year":"2009","journal-title":"J Hepatol"},{"key":"key\n\t\t\t\t20171116025732_CIT0004","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1111\/j.1365-2567.2008.02896.x","article-title":"Hepatitis B virus surface antigen impairs myeloid dendritic cell function: a possible immune escape mechanism of hepatitis B virus","volume":"126","year":"2009","journal-title":"Immunology"},{"key":"key\n\t\t\t\t20171116025732_CIT0005","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1016\/j.jhep.2010.12.042","article-title":"The hepatitis B e antigen (HBeAg) targets and suppresses activation of the toll-like receptor signaling pathway","volume":"55","year":"2011","journal-title":"J Hepatol"},{"key":"key\n\t\t\t\t20171116025732_CIT0006","doi-asserted-by":"crossref","first-page":"2111","DOI":"10.1084\/jem.20072076","article-title":"Functional skewing of the global CD8 T cell population in chronic hepatitis B virus infection","volume":"205","year":"2008","journal-title":"J Exp Med"},{"key":"key\n\t\t\t\t20171116025732_CIT0007","doi-asserted-by":"crossref","first-page":"4215","DOI":"10.1128\/JVI.02844-06","article-title":"Characterization of hepatitis B virus (HBV)-specific T-cell dysfunction in chronic HBV infection","volume":"81","year":"2007","journal-title":"J Virol"},{"key":"key\n\t\t\t\t20171116025732_CIT0008","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.jhep.2012.02.010","article-title":"EASL clinical practice guidelines: Management of chronic hepatitis B virus infection","volume":"57","author":"European Association for the Study of the Liver","year":"2012","journal-title":"J Hepatol"},{"key":"key\n\t\t\t\t20171116025732_CIT0009","doi-asserted-by":"crossref","first-page":"i18","DOI":"10.1136\/gutjnl-2012-302085","article-title":"New perspectives in the therapy of chronic hepatitis B","volume":"61","year":"2012","journal-title":"Gut"},{"key":"key\n\t\t\t\t20171116025732_CIT0010","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1053\/j.gastro.2012.01.044","article-title":"Effectiveness of hepatitis B treatment in clinical practice","volume":"142","year":"2012","journal-title":"Gastroenterology"},{"key":"key\n\t\t\t\t20171116025732_CIT0011","doi-asserted-by":"crossref","first-page":"1462","DOI":"10.1016\/j.cgh.2007.09.005","article-title":"Serum hepatitis B surface antigen quantitation can reflect hepatitis B virus in the liver and predict treatment response","volume":"5","year":"2007","journal-title":"Clin Gastroenterol Hepatol"},{"key":"key\n\t\t\t\t20171116025732_CIT0012","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1002\/hep.22744","article-title":"Early serum HBsAg drop: a strong predictor of sustained virological response to pegylated interferon alfa-2a in HBeAg-negative patients","volume":"49","year":"2009","journal-title":"Hepatology"},{"key":"key\n\t\t\t\t20171116025732_CIT0013","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1111\/liv.12403","article-title":"HBsAg quantification: useful for monitoring natural history and treatment outcome","volume":"34","year":"2014","journal-title":"Liver Int"},{"key":"key\n\t\t\t\t20171116025732_CIT0014","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s12072-015-9675-4","article-title":"Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update","volume":"10","year":"2016","journal-title":"Hepatol Int"},{"key":"key\n\t\t\t\t20171116025732_CIT0015","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1002\/hep.28156","article-title":"AASLD guidelines for treatment of chronic hepatitis B","volume":"63","author":"American Association for the Study of Liver Diseases","year":"2016","journal-title":"Hepatology"},{"key":"key\n\t\t\t\t20171116025732_CIT0016","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1038\/nri2314","article-title":"Interferon-inducible antiviral effectors","volume":"8","year":"2008","journal-title":"Nat Rev Immunol"},{"key":"key\n\t\t\t\t20171116025732_CIT0017","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1128\/CMR.14.4.778-809.2001","article-title":"Antiviral actions of interferons","volume":"14","year":"2001","journal-title":"Clin Microbiol Rev"},{"key":"key\n\t\t\t\t20171116025732_CIT0018","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1053\/j.gastro.2012.07.014","article-title":"Restored function of HBV-specific T cells after long-term effective therapy with nucleos(t)ide analogues","volume":"143","year":"2012","journal-title":"Gastroenterology"},{"key":"key\n\t\t\t\t20171116025732_CIT0019","doi-asserted-by":"crossref","first-page":"i6","DOI":"10.1136\/gutjnl-2012-302056","article-title":"New insight in the pathobiology of hepatitis B virus infection","volume":"61","year":"2012","journal-title":"Gut"},{"key":"key\n\t\t\t\t20171116025732_CIT0020","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1002\/hep.22760","article-title":"Hepatitis B virus surface antigen levels: a guide to sustained response to peginterferon alfa-2a in HBeAg-negative chronic hepatitis B","volume":"49","year":"2009","journal-title":"Hepatology"},{"key":"key\n\t\t\t\t20171116025732_CIT0021","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1136\/gutjnl-2014-307023","article-title":"Entecavir treatment does not eliminate the risk of hepatocellular carcinoma in chronic hepatitis B: limited role for risk scores in Caucasians","volume":"64","author":"VIRGIL Surveillance Study Group","year":"2015","journal-title":"Gut"},{"key":"key\n\t\t\t\t20171116025732_CIT0022","doi-asserted-by":"crossref","first-page":"9913","DOI":"10.1073\/pnas.0504273102","article-title":"Interferon prevents formation of replication-competent hepatitis B virus RNA-containing nucleocapsids","volume":"102","year":"2005","journal-title":"Proc Natl Acad Sci U S A"},{"key":"key\n\t\t\t\t20171116025732_CIT0023","doi-asserted-by":"crossref","first-page":"9332","DOI":"10.1128\/JVI.00918-10","article-title":"Interferons accelerate decay of replication-competent nucleocapsids of hepatitis B virus","volume":"84","year":"2010","journal-title":"J Virol"},{"key":"key\n\t\t\t\t20171116025732_CIT0024","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1172\/JCI58847","article-title":"IFN-\u03b1 inhibits HBV transcription and replication in cell culture and in humanized mice by targeting the epigenetic regulation of the nuclear cccDNA minichromosome","volume":"122","year":"2012","journal-title":"J Clin Invest"},{"key":"key\n\t\t\t\t20171116025732_CIT0025","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1159\/000360941","article-title":"Interferon therapy of chronic hepatitis B","volume":"57","year":"2014","journal-title":"Intervirology"},{"key":"key\n\t\t\t\t20171116025732_CIT0026","doi-asserted-by":"crossref","first-page":"601","DOI":"10.5812\/kowsar.1735143X.451","article-title":"Recent advances in the management of chronic hepatitis B","volume":"11","year":"2011","journal-title":"Hepat Mon"},{"key":"key\n\t\t\t\t20171116025732_CIT0027","doi-asserted-by":"crossref","first-page":"2682","DOI":"10.1056\/NEJMoa043470","article-title":"Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B","volume":"352","author":"Peginterferon Alfa-2a HBeAg-Positive Chronic Hepatitis B Study Group","year":"2005","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20171116025732_CIT0028","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/S0140-6736(05)17701-0","article-title":"Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial","volume":"365","author":"HBV 99-01 Study Group; Rotterdam Foundation for Liver Research","year":"2005","journal-title":"Lancet"},{"key":"key\n\t\t\t\t20171116025732_CIT0029","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1056\/NEJMoa051285","article-title":"A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B","volume":"354","author":"BEHoLD AI463022 Study Group","year":"2006","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20171116025732_CIT0030","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1056\/NEJM199807093390201","article-title":"A one-year trial of lamivudine for chronic hepatitis B. Asia Hepatitis Lamivudine Study Group","volume":"339","year":"1998","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20171116025732_CIT0031","doi-asserted-by":"crossref","first-page":"2576","DOI":"10.1056\/NEJMoa066422","article-title":"Telbivudine versus lamivudine in patients with chronic hepatitis B","volume":"357","author":"Globe Study Group","year":"2007","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20171116025732_CIT0032","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1056\/NEJMoa020681","article-title":"Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B","volume":"348","author":"Adefovir Dipivoxil 437 Study Group","year":"2003","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20171116025732_CIT0033","doi-asserted-by":"crossref","first-page":"2442","DOI":"10.1056\/NEJMoa0802878","article-title":"Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B","volume":"359","year":"2008","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20171116025732_CIT0034","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1053\/j.gastro.2008.10.026","article-title":"2-Year GLOBE trial results: telbivudine Is superior to lamivudine in patients with chronic hepatitis B","volume":"136","author":"GLOBE Study Group","year":"2009","journal-title":"Gastroenterology"},{"key":"key\n\t\t\t\t20171116025732_CIT0035","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1002\/hep.23327","article-title":"Entecavir treatment for up to 5 years in patients with hepatitis B e antigen-positive chronic hepatitis B","volume":"51","year":"2010","journal-title":"Hepatology"},{"key":"key\n\t\t\t\t20171116025732_CIT0036","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1053\/j.gastro.2007.08.025","article-title":"Entecavir therapy for up to 96 weeks in patients with HBeAg-positive chronic hepatitis B","volume":"133","year":"2007","journal-title":"Gastroenterology"},{"key":"key\n\t\t\t\t20171116025732_CIT0037","first-page":"313A","article-title":"Long term treatment with tenofovir disoproxil fumarate for chronic hepatitis B infection is safe and well tolerated and associated with durable virologic response with no detectable resistance: 8 year results from two phase 3 trials","volume":"60","year":"2014","journal-title":"Hepatology"},{"key":"key\n\t\t\t\t20171116025732_CIT0038","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1056\/NEJMoa040431","article-title":"Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B","volume":"351","author":"Peginterferon Alfa-2a HBeAg-Negative Chronic Hepatitis B Study Group","year":"2004","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20171116025732_CIT0039","first-page":"889","article-title":"Efficacy of lamivudine in patients with hepatitis B e antigen-negative\/hepatitis B virus DNA-positive (precore mutant) chronic hepatitis B. Lamivudine Precore Mutant Study Group","volume":"29","year":"1999","journal-title":"Hepatology"},{"key":"key\n\t\t\t\t20171116025732_CIT0040","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1056\/NEJMoa051287","article-title":"Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B","volume":"354","author":"BEHoLD AI463027 Study Group","year":"2006","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20171116025732_CIT0041","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1056\/NEJMoa021812","article-title":"Adefovir dipivoxil for the treatment of hepatitis B e antigen-negative chronic hepatitis B","volume":"348","author":"Adefovir Dipivoxil 438 Study Group","year":"2003","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20171116025732_CIT0042","doi-asserted-by":"crossref","first-page":"1743","DOI":"10.1053\/j.gastro.2006.09.020","article-title":"Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B for up to 5 years","volume":"131","author":"Adefovir Dipivoxil 438 Study Group","year":"2006","journal-title":"Gastroenterology"},{"key":"key\n\t\t\t\t20171116025732_CIT0043","first-page":"888","article-title":"The guideline of prevention and treatment for chronic hepatitis B: a 2015 update [in Chinese]","volume":"23","author":"Chinese Society of Hepatology, Chinese Medical Association; Chinese Society of Infectious Diseases, Chinese Medical Association","year":"2015","journal-title":"Zhonghua Gan Zang Bing Za Zhi"},{"key":"key\n\t\t\t\t20171116025732_CIT0044","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.jhep.2012.11.007","article-title":"Dissecting the divergent effects of interferon-alpha on immune cells: time to rethink combination therapy in chronic hepatitis B?","volume":"58","year":"2013","journal-title":"J Hepatol"},{"key":"key\n\t\t\t\t20171116025732_CIT0045","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1016\/j.jhep.2014.10.002","article-title":"An integration of deep viral suppression with sequential immune modulation (cocktail therapy) to restore antiviral capacity: the future of chronic hepatitis B?","volume":"62","year":"2015","journal-title":"J Hepatol"},{"key":"key\n\t\t\t\t20171116025732_CIT0046","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.3851\/IMP1466","article-title":"A randomized controlled trial of pegylated interferon-alpha2a plus adefovir dipivoxil for hepatitis B e antigen-negative chronic hepatitis B","volume":"14","year":"2009","journal-title":"Antivir Ther"},{"key":"key\n\t\t\t\t20171116025732_CIT0047","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1002\/hep.21282","article-title":"Peginterferon alpha-2b plus adefovir induce strong cccDNA decline and HBsAg reduction in patients with chronic hepatitis B","volume":"44","year":"2006","journal-title":"Hepatology"},{"key":"key\n\t\t\t\t20171116025732_CIT0048","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.jhep.2014.08.021","article-title":"Telbivudine plus pegylated interferon alfa-2a in a randomized study in chronic hepatitis B is associated with an unexpected high rate of peripheral neuropathy","volume":"62","year":"2015","journal-title":"J Hepatol"},{"key":"key\n\t\t\t\t20171116025732_CIT0049","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1053\/j.gastro.2015.09.043","article-title":"Combination of tenofovir disoproxil fumarate and peginterferon \u03b1-2a increases loss of hepatitis B surface antigen in patients with chronic hepatitis B","volume":"150","author":"Study 149 Investigators","year":"2016","journal-title":"Gastroenterology"},{"key":"key\n\t\t\t\t20171116025732_CIT0050","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1016\/j.jhep.2014.05.004","article-title":"HBsAg loss in patients treated with peginterferon alfa-2a and adefovir is associated with SLC16A9 gene variation and lower plasma carnitine levels","volume":"61","year":"2014","journal-title":"J Hepatol"},{"key":"key\n\t\t\t\t20171116025732_CIT0051","article-title":"HLA-C and KIR combined genotype as new response marker for HBeAg-positive chronic hepatitis B patients treated with interferon-based combination therapy","year":"2016","journal-title":"J Viral Hepat"},{"key":"key\n\t\t\t\t20171116025732_CIT0052","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1111\/jvh.12467","article-title":"A randomized clinical trial of peginterferon alpha-2b with or without entecavir in patients with HBeAg-negative chronic hepatitis B: Role of host and viral factors associated with treatment response","volume":"23","year":"2016","journal-title":"J Viral Hepat"},{"key":"key\n\t\t\t\t20171116025732_CIT0053","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1016\/j.jhep.2014.05.044","article-title":"Switching from entecavir to PegIFN alfa-2a in patients with HBeAg-positive chronic hepatitis B: a randomised open-label trial (OSST trial)","volume":"61","year":"2014","journal-title":"J Hepatol"},{"key":"key\n\t\t\t\t20171116025732_CIT0054","doi-asserted-by":"crossref","first-page":"337","DOI":"10.3851\/IMP3019","article-title":"Sustained immune control in HBeAg-positive patients who switched from entecavir therapy to pegylated interferon-\u03b12a: 1 year follow-up of the OSST study","volume":"21","year":"2016","journal-title":"Antivir Ther"},{"key":"key\n\t\t\t\t20171116025732_CIT0055","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1111\/j.1365-2893.2010.01332.x","article-title":"Sequential therapy with adefovir dipivoxil and pegylated interferon alfa-2a for HBeAg-negative patients","volume":"18","year":"2011","journal-title":"J Viral Hepat"},{"key":"key\n\t\t\t\t20171116025732_CIT0056","doi-asserted-by":"crossref","first-page":"2463","DOI":"10.1111\/j.1572-0241.2005.00247.x","article-title":"Higher efficacy of sequential therapy with interferon-alpha and lamivudine combination compared to lamivudine monotherapy in HBeAg positive chronic hepatitis B patients","volume":"100","year":"2005","journal-title":"Am J Gastroenterol"},{"key":"key\n\t\t\t\t20171116025732_CIT0057","doi-asserted-by":"crossref","first-page":"e11","DOI":"10.1111\/jvh.12018","article-title":"Sequential therapy with entecavir and PEG-INF in patients affected by chronic hepatitis B and high levels of HBV-DNA with non-D genotypes","volume":"20","year":"2013","journal-title":"J Viral Hepat"},{"key":"key\n\t\t\t\t20171116025732_CIT0058"},{"key":"key\n\t\t\t\t20171116025732_CIT0059"},{"key":"key\n\t\t\t\t20171116025732_CIT0060","first-page":"105","article-title":"The role of HBsAg levels in the current management of chronic HBV infection","volume":"27","year":"2014","journal-title":"Ann Gastroenterol"},{"key":"key\n\t\t\t\t20171116025732_CIT0061","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1007\/s12072-011-9280-0","article-title":"Hepatitis B surface antigen: association with sustained response to peginterferon alfa-2a in hepatitis B e antigen-positive patients","volume":"7","year":"2013","journal-title":"Hepatol Int"},{"key":"key\n\t\t\t\t20171116025732_CIT0062","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.jcv.2012.01.024","article-title":"Adding pegylated interferon to a current nucleos(t)ide therapy leads to HBsAg seroconversion in a subgroup of patients with chronic hepatitis B","volume":"54","year":"2012","journal-title":"J Clin Virol"},{"key":"key\n\t\t\t\t20171116025732_CIT0063","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1016\/j.jcv.2013.09.020","article-title":"Add-on peg-interferon leads to loss of HBsAg in patients with HBeAg-negative chronic hepatitis and HBV DNA fully suppressed by long-term nucleotide analogs","volume":"58","year":"2013","journal-title":"J Clin Virol"},{"key":"key\n\t\t\t\t20171116025732_CIT0064","doi-asserted-by":"crossref","first-page":"1512","DOI":"10.1002\/hep.27586","article-title":"Adding pegylated interferon to entecavir for hepatitis B e antigen-positive chronic hepatitis B: A multicenter randomized trial (ARES study)","volume":"61","author":"ARES Study Group","year":"2015","journal-title":"Hepatology"},{"key":"key\n\t\t\t\t20171116025732_CIT0065","doi-asserted-by":"crossref","first-page":"1714","DOI":"10.1093\/cid\/ciu702","article-title":"A randomized, open-label clinical study of combined pegylated interferon Alfa-2a (40KD) and entecavir treatment for hepatitis B \u201ce\u201d antigen-positive chronic hepatitis B","volume":"59","year":"2014","journal-title":"Clin Infect Dis"},{"key":"key\n\t\t\t\t20171116025732_CIT0066","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1016\/j.jhep.2009.12.017","article-title":"The molecular basis of the failed immune response in chronic HBV: therapeutic implications","volume":"52","year":"2010","journal-title":"J Hepatol"},{"key":"key\n\t\t\t\t20171116025732_CIT0067","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1128\/JVI.77.1.68-76.2003","article-title":"CD8(+) T cells mediate viral clearance and disease pathogenesis during acute hepatitis B virus infection","volume":"77","year":"2003","journal-title":"J Virol"},{"key":"key\n\t\t\t\t20171116025732_CIT0068","doi-asserted-by":"crossref","first-page":"4858","DOI":"10.3748\/wjg.v13.i36.4858","article-title":"Regulatory T cells in viral hepatitis","volume":"13","year":"2007","journal-title":"World J Gastroenterol"},{"key":"key\n\t\t\t\t20171116025732_CIT0069","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.jhep.2012.09.029","article-title":"Differential boosting of innate and adaptive antiviral responses during pegylated-interferon-alpha therapy of chronic hepatitis B","volume":"58","year":"2013","journal-title":"J Hepatol"},{"key":"key\n\t\t\t\t20171116025732_CIT0070","doi-asserted-by":"crossref","first-page":"877","DOI":"10.3851\/IMP2630","article-title":"Reduced Toll-like receptor 3 expression in chronic hepatitis B patients and its restoration by interferon therapy","volume":"18","year":"2013","journal-title":"Antivir Ther"},{"key":"key\n\t\t\t\t20171116025732_CIT0071","doi-asserted-by":"crossref","first-page":"637","DOI":"10.3851\/IMP2762","article-title":"Reduced toll-like receptor 9 expression on peripheral CD14+ monocytes of chronic hepatitis B patients and its restoration by effective therapy","volume":"19","year":"2014","journal-title":"Antivir Ther"},{"key":"key\n\t\t\t\t20171116025732_CIT0072","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1016\/j.jhep.2011.12.032","article-title":"Peginterferon-\u03b1 does not improve early peripheral blood HBV-specific T-cell responses in HBeAg-negative chronic hepatitis","volume":"56","year":"2012","journal-title":"J Hepatol"},{"key":"key\n\t\t\t\t20171116025732_CIT0073","doi-asserted-by":"crossref","first-page":"e1001227","DOI":"10.1371\/journal.ppat.1001227","article-title":"Blockade of immunosuppressive cytokines restores NK cell antiviral function in chronic hepatitis B virus infection","volume":"6","year":"2010","journal-title":"PLoS Pathog"},{"key":"key\n\t\t\t\t20171116025732_CIT0074","doi-asserted-by":"crossref","first-page":"S18","DOI":"10.1016\/S0168-8278(12)60056-7","article-title":"Pegylated-interferon-alpha alone or in combination with entecavir restores ISG responsiveness and reduces intrahepatic viral loads and antigenemia in hepatitis B virus infected humanized mice","volume":"56","year":"2012","journal-title":"J Hepatol"},{"key":"key\n\t\t\t\t20171116025732_CIT0075","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1016\/j.jhep.2015.10.013","article-title":"Restoration of T cell function in chronic hepatitis B patients upon treatment with interferon based combination therapy","volume":"64","year":"2016","journal-title":"J Hepatol"},{"key":"key\n\t\t\t\t20171116025732_CIT0076","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.jhep.2013.08.020","article-title":"Reduction of HBV replication prolongs the early immunological response to IFN\u03b1 therapy","volume":"60","year":"2014","journal-title":"J Hepatol"},{"key":"key\n\t\t\t\t20171116025732_CIT0077","doi-asserted-by":"crossref","first-page":"591","DOI":"10.3851\/IMP2953","article-title":"Upregulation of NKG2C+ natural killer cells, TLR-2 expression on monocytes and downregulation of regulatory T-cells influence PEG-IFN treatment efficacy in entecavir-suppressed patients with CHB","volume":"20","year":"2015","journal-title":"Antivir Ther"},{"key":"key\n\t\t\t\t20171116025732_CIT0078","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1111\/apt.13694","article-title":"Review article: novel therapies for hepatitis B virus cure - advances and perspectives","volume":"44","year":"2016","journal-title":"Aliment Pharmacol Ther"},{"key":"key\n\t\t\t\t20171116025732_CIT0079","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1038\/nrgastro.2015.8","article-title":"Viral hepatitis. HBV cure\u2013can we pin our hopes on immunotherapy?","volume":"12","year":"2015","journal-title":"Nat Rev Gastroenterol Hepatol"}],"container-title":["The Journal of Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jid\/article-pdf\/216\/suppl_8\/S771\/21796962\/jix355.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,31]],"date-time":"2022-07-31T12:10:24Z","timestamp":1659269424000},"score":1,"resource":{"primary":{"URL":"http:\/\/academic.oup.com\/jid\/article\/216\/suppl_8\/S771\/4636137"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,10,15]]},"references-count":79,"journal-issue":{"issue":"suppl_8","published-online":{"date-parts":[[2017,11,16]]},"published-print":{"date-parts":[[2017,11,16]]}},"URL":"https:\/\/doi.org\/10.1093\/infdis\/jix355","relation":{},"ISSN":["0022-1899","1537-6613"],"issn-type":[{"value":"0022-1899","type":"print"},{"value":"1537-6613","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2017,10,15]]},"published":{"date-parts":[[2017,10,15]]}}}